Uni-Bio Science Group マネジメント

マネジメント基準チェック /44

Uni-Bio Science Groupの CEO はFrank Zhaoで、 Apr2019年に任命され、の在任期間は 5.58年です。の年間総報酬はHK$ 900.00Kで、 67.1%給与と32.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.13%を直接所有しており、その価値はHK$ 507.48K 。経営陣と取締役会の平均在任期間はそれぞれ4.3年と7.4年です。

主要情報

Frank Zhao

最高経営責任者

HK$900.0k

報酬総額

CEO給与比率	67.1%
CEO在任期間	5.6yrs
CEOの所有権	0.1%
経営陣の平均在職期間	4.3yrs
取締役会の平均在任期間	7.4yrs

経営陣の近況

Recent updates

Uni-Bio Science Group Limited (HKG:690) Surges 35% Yet Its Low P/E Is No Reason For Excitement

Sep 13

Earnings Working Against Uni-Bio Science Group Limited's (HKG:690) Share Price Following 26% Dive

Jul 29

Earnings Working Against Uni-Bio Science Group Limited's (HKG:690) Share Price Following 27% Dive

May 27

Is Uni-Bio Science Group (HKG:690) Using Too Much Debt?

Apr 24

Uni-Bio Science Group Limited (HKG:690) Held Back By Insufficient Growth Even After Shares Climb 28%

Jan 22

Uni-Bio Science Group Limited's (HKG:690) Low P/S No Reason For Excitement

Oct 24

Robust Earnings May Not Tell The Whole Story For Uni-Bio Science Group (HKG:690)

Apr 30

We're Interested To See How Uni-Bio Science Group (HKG:690) Uses Its Cash Hoard To Grow

Nov 22

Estimating The Fair Value Of Uni-Bio Science Group Limited (HKG:690)

Jan 05

Companies Like Uni-Bio Science Group (HKG:690) Can Afford To Invest In Growth

Mar 01

Uni-Bio Science Group (HKG:690) Share Prices Have Dropped 26% In The Last Five Years

Jan 05

We're Interested To See How Uni-Bio Science Group (HKG:690) Uses Its Cash Hoard To Grow

Nov 23

CEO報酬分析

Uni-Bio Science Group の収益と比較して、Frank Zhao の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	HK$99m
Mar 31 2024	n/a	n/a	HK$85m
Dec 31 2023	HK$900k	HK$604k	HK$71m
Sep 30 2023	n/a	n/a	HK$67m
Jun 30 2023	n/a	n/a	HK$63m
Mar 31 2023	n/a	n/a	HK$51m
Dec 31 2022	HK$1m	HK$1m	HK$39m
Sep 30 2022	n/a	n/a	HK$16m
Jun 30 2022	n/a	n/a	-HK$7m
Mar 31 2022	n/a	n/a	-HK$13m
Dec 31 2021	HK$2m	HK$907k	-HK$20m
Sep 30 2021	n/a	n/a	-HK$39m
Jun 30 2021	n/a	n/a	-HK$58m
Mar 31 2021	n/a	n/a	-HK$65m
Dec 31 2020	HK$3m	HK$886k	-HK$71m
Sep 30 2020	n/a	n/a	-HK$63m
Jun 30 2020	n/a	n/a	-HK$54m
Mar 31 2020	n/a	n/a	-HK$26m
Dec 31 2019	HK$3m	HK$600k	HK$2m
Sep 30 2019	n/a	n/a	-HK$14m
Jun 30 2019	n/a	n/a	-HK$30m
Mar 31 2019	n/a	n/a	-HK$85m
Dec 31 2018	HK$227k	n/a	-HK$139m
Sep 30 2018	n/a	n/a	-HK$224m
Jun 30 2018	n/a	n/a	-HK$309m
Mar 31 2018	n/a	n/a	-HK$294m
Dec 31 2017	HK$360k	n/a	-HK$279m

報酬と市場: Frankの総報酬 ($USD 115.64K ) は、 Hong Kong市場 ($USD 233.55K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Frankの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Frank Zhao (59 yo)

5.6yrs

在職期間

HK$900,000

報酬

Mr. Zhi Gang Zhao, also known as Frank, CPA, MSc, has been the Chief Executive Officer and Executive Director of Uni-Bio Science Group Limited since April 8, 2019. He has been the Chief Financial Officer a...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Kingsley Leung	Executive Chairman of the Board	10.8yrs	HK$1.60m	27.65% HK$ 104.0m
Zhi Gang Zhao	CEO & Executive Director	5.6yrs	HK$900.00k	0.13% HK$ 507.5k
Dawei Chen	Executive Vice Chairman of the Board	7.8yrs	HK$284.00k	2.87% HK$ 10.8m
Kai Du	Financial Controller	2.7yrs	データなし	データなし
Wei Tian	Head of HR & Administration Department	no data	データなし	データなし
Wen Du An	Head of Marketing & Sales	4.3yrs	データなし	データなし
Ya Lei Wen	Head of Manufacture Department	no data	データなし	データなし
HuaNan Zhao	Head of Medicine & Registration Department	no data	データなし	データなし
Jing Li	Head of R&D Department	no data	データなし	データなし
Wing Yan Ho	Company Secretary	2.7yrs	データなし	データなし

4.3yrs

平均在職期間

43.5yo

平均年齢

経験豊富な経営陣: 690の経営陣は経験豊富であると考えられます ( 4.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Kingsley Leung	Executive Chairman of the Board	10.8yrs	HK$1.60m	27.65% HK$ 104.0m
Zhi Gang Zhao	CEO & Executive Director	10.6yrs	HK$900.00k	0.13% HK$ 507.5k
Dawei Chen	Executive Vice Chairman of the Board	7.8yrs	HK$284.00k	2.87% HK$ 10.8m
Qingshan Ma	Independent Non-Executive Director	5.6yrs	HK$120.00k	データなし
Kai Ming Chow	Independent Non-Executive Director	8.6yrs	HK$120.00k	データなし
Qimin Ren	Independent Non-Executive Director	7yrs	HK$120.00k	データなし
Kwok Wing Yau	Non-Executive Director	5.6yrs	HK$120.00k	1.69% HK$ 6.3m
Qing Zhang	Non-Executive Director	no data	データなし	データなし

7.4yrs

平均在職期間

54yo

平均年齢

経験豊富なボード: 690の取締役会は経験豊富であると考えられます ( 7.4年の平均在任期間)。

Uni-Bio Science Group マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Uni-Bio Science Group Limited, Annual General Meeting, May 16, 2024

Uni-Bio Science Group Limited Appoints Zhang Yanfen as an Executive Director

Less than half of directors are independent

Less than half of directors are independent

Uni-Bio Science Group Limited, Annual General Meeting, May 16, 2022

Uni-Bio Science Group Limited Announces Executive Changes

Recent updates

Uni-Bio Science Group Limited (HKG:690) Surges 35% Yet Its Low P/E Is No Reason For Excitement

Uni-Bio Science Group Limited (SEHK:690) commences an Equity Buyback Plan for 616,358,814 shares, representing 10% of its issued share capital, under the authorization approved on May 16, 2024.

Uni-Bio Science Group Limited to Report First Half, 2024 Results on Aug 28, 2024

Earnings Working Against Uni-Bio Science Group Limited's (HKG:690) Share Price Following 26% Dive

New minor risk - Share price stability

Earnings Working Against Uni-Bio Science Group Limited's (HKG:690) Share Price Following 27% Dive

Is Uni-Bio Science Group (HKG:690) Using Too Much Debt?

Uni-Bio Science Group Limited, Annual General Meeting, May 16, 2024

Full year 2023 earnings released: EPS: HK$0.011 (vs HK$0.006 in FY 2022)

Uni-Bio Science Group Limited to Report Q4, 2023 Results on Mar 27, 2024

Uni-Bio Science Group Limited Announces the Acceptance of its Marketing Application for Diquafosol Sodium Eye Drops by the China National Medical Products Administration

Uni-Bio Science Group Limited (HKG:690) Held Back By Insufficient Growth Even After Shares Climb 28%

Uni-Bio Science Group Limited Announces Approval of Marketing Application of Bogutai (Teriparatide Injection) by the China National Medical Products Administration

Uni-Bio Science Group Limited's (HKG:690) Low P/S No Reason For Excitement

First half 2023 earnings released: EPS: HK$0.006 (vs HK$0.002 in 1H 2022)

Uni-Bio Science Group Limited to Report First Half, 2023 Results on Aug 28, 2023

Uni-Bio Science Group Limited Appoints Zhang Yanfen as an Executive Director

Robust Earnings May Not Tell The Whole Story For Uni-Bio Science Group (HKG:690)

Full year 2022 earnings released: EPS: HK$0.006 (vs HK$0.003 loss in FY 2021)

We're Interested To See How Uni-Bio Science Group (HKG:690) Uses Its Cash Hoard To Grow

Less than half of directors are independent

First half 2022 earnings released: EPS: HK$0.002 (vs HK$0 in 1H 2021)

Uni-Bio Science Group Limited to Report First Half, 2022 Results on Aug 29, 2022

Uni-Bio Science Group Limited Announces Marketing Application of Bogutai (Teriparatide Injection) Officially Accepted by the China National Medical Products Administration

Less than half of directors are independent

Uni-Bio Science Group Limited, Annual General Meeting, May 16, 2022

Uni-Bio Science Group Limited Announces Executive Changes

Estimating The Fair Value Of Uni-Bio Science Group Limited (HKG:690)

Uni-Bio Science Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2021

Uni-Bio Science Group Limited to Report Fiscal Year 2020 Results on Mar 29, 2021

Companies Like Uni-Bio Science Group (HKG:690) Can Afford To Invest In Growth

Uni-Bio Science Group (HKG:690) Share Prices Have Dropped 26% In The Last Five Years

Uni-Bio Science Group Limited Announces BOSHUTAI (Acarbose Tablets) Has Been Granted Approval for Marketing in China by the National Medical Products Administration

We're Interested To See How Uni-Bio Science Group (HKG:690) Uses Its Cash Hoard To Grow

Uni-Bio Science Group Limited Updates on the Developmental Potential of the Group's Innovative Biologic Self-Developed Drug Recombinant Exendin-4 Injection

First half earnings released

Uni-Bio Science Group Limited to Report Q1, 2021 Results on Aug 28, 2020

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /44